TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.

Justin M OldhamShwu-Fan MaFernando J MartinezKevin J AnstromGanesh RaghuDavid A SchwartzEleanor ValenziLeah WittCathryn LeeRekha VijYong HuangMary E StrekImre Nothnull null

Published in: American journal of respiratory and critical care medicine (2016)

NAC may be an efficacious therapy for individuals with IPF with an rs3750920 (TOLLIP) TT genotype, but it was associated with a trend toward harm in those with a CC genotype. A genotype-stratified prospective clinical trial should be conducted before any recommendation regarding the use of off-label NAC to treat IPF.

Keyphrases

idiopathic pulmonary fibrosis
clinical trial
transcription factor
interstitial lung disease
open label
randomized controlled trial
rheumatoid arthritis
systemic sclerosis
phase iii